aRetrospective database claims analysis that assessed hospitalizations, ED visits, iMCD-related comorbidities, and organ failure in US patients with Castleman disease (over 30 million) between January 1, 2017, and December 31, 2019. Minor criteria from the Castleman Disease Collaborative Network (CDCN) diagnostic criteria were applied to ensure that the patients had iMCD.1,3
There are various therapies being used in the treatment of patients with iMCD. The CDCN, the
same group that published the first consensus diagnostic criteria, has developed formal
guidelines for the treatment of iMCD.5
Timely diagnosis and appropriate treatment can help bring the symptoms of iMCD under
Considering the chronic and progressive nature of iMCD, patients will need to receive
ongoing treatment to keep their symptoms under control.5,6
Evidence-based treatment guidelines have been developed to help healthcare professionals
treat their patients with iMCD.5
Hear from the people who have been fighting iMCD for years, and learn how they have dealt
with some of the challenges they have experienced.
In 2005, Jessica began experiencing fever, night sweats, and swollen lymph nodes. After 14 long years, she found out that she has iMCD. Watch her story to learn about her journey to diagnosis.
In 1985, there weren’t any guidelines to diagnose iMCD. But that didn’t stop Carl from
getting an accurate diagnosis for his rare disease. Watch his journey to learn about the
path he took to finally get diagnosed with iMCD.
iMCD has troubled Frank for years. But with his wife Dina by his side, he was never going
to back down. Watch the video to learn about the ups and downs they faced during their
journey to diagnosis.
"*" indicates required fields
Mukherjee S, Martin R, Sande B, et al. A longitudinal population level analysis of healthcare resource utilization, comorbidity, and survival in idiopathic multicentric Castleman disease patients. Presented at: 62nd American Society of Hematology (ASH) Annual Meeting and Exposition; December 5-8, 2020; virtual meeting.
Mukherjee S, Martin R, Sande B, et al. A longitudinal population level analysis of healthcare resource utilization, comorbidity, and survival in idiopathic multicentric Castleman disease patients. Blood. 2020;136(suppl 1):11.
Fajgenbaum DC, Uldrick TS, Bagg A, et al. International, evidence-based consensus diagnostic criteria for HHV-8–negative/idiopathic multicentric Castleman disease. Blood. 2017;129(12):1646-1657.
Mukherjee S, Martin R, Sande B, Paige JS, Fajgenbaum DC. Epidemiology and treatment patterns of idiopathic multicentric Castleman disease in the era of IL-6-directed therapy. Blood Adv. 2022;6(2):359-367.
van Rhee F, Voorhees P, Dispenzieri A, et al. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood. 2018;132(20):2115 -2124.
Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for B-Cell Lymphomas V.3.2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed April 29, 2022. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
If so, you will be directed to the website that contains information intended for US healthcare professionals.
Save and use this Patient Diary online with your Google account by selecting “Google Sheet” and then “Use Template,” or download to your computer by selecting “Excel File.”
No data is stored by or transferred to this KnowiMCD.com website. This site contains links to other websites, and these links will direct users to third-party sites.
Please wait a moment.
If so, you will be directed to the website that contains information intended for a US audience.
Viral hemophagocytic lymphohistiocytosis.
A doctor who specializes in the branch of medicine that deals with rheumatic conditions.
Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes.
Positron emission tomography (PET) is a method of producing a 3-dimensional image of the internal
structures of body tissues after administering a natural biochemical substance like glucose or fatty
acids. These images are generated with the help of a computer.
A doctor who evaluates the changes caused by disease in tissues and body fluids and helps reach a
A doctor who specializes in the diagnosis and treatment of kidney abnormalities.
Macrophage activation syndrome.
Malignancy-associated hemophagocytic lymphohistiocytosis.
A disease in which cells of the lymph system grow excessively
Lymph nodes make immune cells that help the body fight infection.
A key signaling molecule that helps to regulate the body’s immune system.
Infectious disease medicine is the subspecialty of internal medicine that focuses on diagnosing and
A rare condition that affects multiple groups of lymph nodes throughout the body. Patients with iMCD
are HIV negative and HHV-8 negative.
The underlying cause or origin of a disease is unknown.
Human immunodeficiency virus.
A doctor who specializes in the branch of medical science that deals with cancers of the blood and
Powerful molecules that are normally secreted by the cells of the immune system in response to
infectious or noninfectious agents.
An overreaction of the body’s immune system in which too many cytokines are released into the
bloodstream very quickly, with potentially severe or life-threatening effects.
Computed tomography (CT) is a method of producing an image of the internal structures by passing an
x‑ray through the body.
The removal and examination of tissue, cells, or fluids from the body.
A condition in which the body’s immune system accidentally attacks itself.
Autoimmune lymphoproliferative syndrome.
Please click “OK” to continue or “CANCEL” to return to KnowiMCD.com